Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

9.890 -0.150 (-1.49%)
Streaming Delayed Price Updated: 9:49 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroGen, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher ↗
 
Via Benzinga
News headline image
Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program ↗
FibroGen reports topline results from late-stage trials of pamrevlumab for pancreatic cancer, failing to meet the primary endpoint of overall survival. 
Via Benzinga
News headline image
Ground Cinnamon Recalls: What to Know as FDA Issues Alert Over Lead Levels ↗
New ground cinnamon recalls are in effect as the FDA warns consumers about increased lead levels in some of these products. 
Via InvestorPlace
Topics Product Recall
News headline image
Why Are Chip Stocks Up Today? ↗
Chip stocks are up today and investors wondering why will find all of the news explaining the rally in the sector on Wednesday. 
Via InvestorPlace
News headline image
FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts ↗
FibroGen layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. 
Via InvestorPlace
Topics Workforce
News headline image
Why is Macrogenics (MGNX) Stock Down 28% Today? ↗
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
News headline image
Why Is FibroGen (FGEN) Stock Down 44% Today? ↗
FibroGen stock is down on Wednesday as FGEN investors react to the company's failed clinical trials for its pancreatic cancer treatment. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
News headline image
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Going On With FibroGen Stock Tuesday? ↗
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! 
Via InvestorPlace
News headline image
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
FibroGen Stock Is Surging After The Bell: What's Going On? ↗
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
7 Penny Biotech Stocks to Triple Your Investment ↗
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Via AB Newswire
News headline image
FibroGen Shares Climb On Strong Q1 Sales ↗
FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902... 
Via Benzinga
News headline image
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday! 
Via InvestorPlace
News headline image
FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 ↗
FGEN stock results show that FibroGen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape ↗
FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements... 
Via Benzinga
News headline image
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day ↗
Selling these three NASDAQ stocks might be the best option now, as they continue to show potential issues and continued weakness. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.